<strong>Good</strong> <strong>Health</strong> <strong>Can’t</strong> <strong>Wait</strong>. Dr. Reddy’s Laboratories Limited NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.5: PROVISIONS (CONTINUED) PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 (a) Details of changes in allowance for sales returns are as follows: Balance at the beginning of the year 2,504 1,906 Provision made during the year 3,536 2,451 Provision utilised during the year (2,135) (1,853) Balance at the end of the year 3,905 2,504 2.6: TRADE PAYABLES PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 Trade payables Due to micro, small and medium enterprises 79 97 Others 8,594 8,835 8,673 8,932 (a) The principal amount remaining unpaid as at 31 March 2015 in respect of enterprises covered under the “Micro, Small and Medium Enterprises Development Act, 2006” (MSMDA) is ` 79 (previous year: ` 97). The interest amount computed based on the provisions under Section 16 of the MSMDA of ` 0.09 (previous year: ` 0.03) is remaining unpaid as of 31 March 2015. The interest amount of ` 0.03 that remained unpaid as at 31 March 2014 was paid fully during the current year. (b) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this Act is ` Nil (previous year: ` Nil). (c) The list of undertakings covered under MSMDA was determined by the Company on the basis of information available with the Company and has been relied upon by the auditors. 184
Consolidated Financial Statements Annual Report 2014 - 15 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.7: FIXED ASSETS GROSS BLOCK DEPRECIATION / AMORTISATION / IMPAIRMENT NET BLOCK DESCRIPTION Tangible Assets AS AT ADDITIONS DELETIONS 1 APRIL 2014 FOREIGN EXCHANGE ADJUSTMENTS (a) AS AT 31 MARCH 2015 AS AT 1 APRIL 2014 DEPRECI- ATION / AMORTISA- TION FOR THE YEAR IMPAIRMENT DELETIONS (b) FOREIGN EXCHANGE ADJUSTMENTS (a) Land 3,799 12 1 (63) 3,747 - - - - - - 3,747 3,799 Buildings Owned 14,042 1,246 60 52 15,280 2,687 595 - 24 2 3,260 12,020 11,355 Assets taken on finance lease 965 2 - (152) 815 169 48 - - (42) 175 640 796 Leasehold improvements 439 121 - - 560 31 52 - - - 83 477 408 Plant and machinery Owned 30,634 6,118 926 (236) 35,590 15,027 3,274 - 736 (123) 17,442 18,148 15,607 Assets taken on finance lease 13 - - (2) 11 5 3 - - (1) 7 4 8 Electrical equipment 3,345 1,260 12 5 4,598 1,649 462 - 10 1 2,102 2,496 1,696 Laboratory equipment Owned 5,388 1,151 152 (46) 6,341 3,001 635 - 105 (19) 3,512 2,829 2,387 Assets taken on finance lease 5 - - - 5 5 - - - - 5 - - Furniture, fixtures and office equipment Owned 3,799 536 216 (48) 4,071 2,634 501 - 184 (35) 2,916 1,155 1,165 Assets taken on finance lease 1 - - - 1 1 - - - - 1 - - Vehicles Owned 263 63 82 (3) 241 201 37 - 73 (1) 164 77 62 Assets taken on finance lease 254 109 - - 363 41 78 - - - 119 244 213 Total tangible assets (A) 62,947 10,618 1,449 (493) 71,623 25,451 5,685 - 1,133 (218) 29,786 41,837 37,496 Previous Year 52,474 10,581 990 882 62,947 21,058 4,724 - 603 272 25,451 37,496 Intangible assets <strong>Good</strong>will 37,683 259 - (6,008) 31,934 31,735 1,009 - - (5,213) 27,531 4,403 5,948 Customer contracts 746 - - 22 768 730 14 - - 20 764 4 16 Copyrights and patents (including 16,119 - - (2,052) 14,067 14,125 353 - - (2,117) 12,361 1,706 1,994 marketing / distribution rights) Technical know how 673 11 - - 684 617 23 - - - 640 44 56 Product related intangible 982 5,454 - (73) 6,363 110 468 267 - (8) 837 5,526 872 Others 26 271 - - 297 - 47 - - - 47 250 26 Total intangible assets (B) 56,229 5,995 - (8,111) 54,113 47,317 1,914 267 - (7,318) 42,180 11,933 8,912 Previous year 48,420 597 319 7,531 56,229 39,330 1,751 - 231 6,467 47,317 8,912 Total (A+B) 119,176 16,613 1,449 (8,604) 125,736 72,768 7,599 267 1,133 (7,536) 71,966 53,770 46,408 Previous year 100,894 11,178 1,309 8,413 119,176 60,388 6,475 - 834 6,739 72,768 46,408 AS AT 31 MARCH 2015 AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 (a) Foreign exchange adjustments represents exchange differences resulting from translation of fixed assets relating to non-integral foreign operations. (b) Based on the performance of and expected cash flows from some of the product related intangibles, the Company reassessed the recoverable amounts of such intangibles and determined that their carrying amount was higher than the recoverable amount. Accordingly, an amount of ` 267 was recorded as an impairment loss during the year ended 31 March 2015 under “Other expenses”. (c ) The Company has capitalised borrowing cost of ` 31 (previous year: ` 77) during the year ended 31 March 2015. (d) Additions to product related intangibles during the year 31 March 2015 includes ` 5,097 towards the acquisition from Novartis Consumer <strong>Health</strong> Inc. of the title and rights to its Habitrol® brand. Refer to Note 2.41 for further details. 185